Who are Caroxime sodium sulfonate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bloxiverz, Razadyne, Camptosar, Camptosar, Zantac, Lorfan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/caroxime-sodium-sulfonate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Caroxime sodium sulfonate — Competitive Intelligence Brief

Caroxime sodium sulfonate (Caroxime sodium sulfonate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholinesterase reactivator (oxime). Area: Toxicology / Antidote.

marketed Acetylcholinesterase reactivator (oxime) Acetylcholinesterase Toxicology / Antidote Small molecule Live · refreshed every 30 min

Target snapshot

Caroxime sodium sulfonate (Caroxime sodium sulfonate) — Chengdu University of Traditional Chinese Medicine. Caroxime sodium sulfonate is an oxime compound that acts as an acetylcholinesterase reactivator, restoring cholinergic neurotransmission by removing phosphoryl groups from inhibited enzyme active sites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Caroxime sodium sulfonate TARGET	Caroxime sodium sulfonate	Chengdu University of Traditional Chinese Medicine	marketed	Acetylcholinesterase reactivator (oxime)	Acetylcholinesterase
Bloxiverz	NEOSTIGMINE	Fresenius Kabi	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2013-01-01
Razadyne	GALANTAMINE	Johnson & Johnson	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2001-01-01
Camptosar	onivyde	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Camptosar	Irinotecan Hydrochloride	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Zantac	ranitidine	GSK (originally Glaxo)	marketed	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Lorfan	LEVALLORPHAN	Roche	marketed	levallorphan	Mu-type opioid receptor, Acetylcholinesterase, Mu-type opioid receptor	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-01-06 — Camptosar · 8329213 · US
2027-01-06 — Camptosar · 8329213 · Compound · US
2028-08-29 — Camptosar · 8147867 · Compound · US
2028-08-29 — Camptosar · 8147867 · US
2033-06-12 — Camptosar · 9364473 · US
2033-06-12 — Camptosar · 9452162 · US
2033-06-12 — Camptosar · 9492442 · US
2033-06-12 — Camptosar · 9717724 · US
2033-06-12 — Camptosar · 9717724 · Method of Use · US
2033-06-12 — Camptosar · 9364473 · Method of Use · US
2033-06-12 — Camptosar · 12364691 · Method of Use · US
2033-06-12 — Camptosar · 11369597 · Method of Use · US
2033-06-12 — Camptosar · 9339497 · Method of Use · US
2033-06-12 — Camptosar · 9452162 · Method of Use · US
2033-06-12 — Camptosar · 9492442 · Method of Use · US
2033-06-12 — Camptosar · 10980795 · US
2033-06-12 — Camptosar · 11369597 · US
2033-06-12 — Camptosar · 9339497 · US
2033-06-12 — Camptosar · 10980795 · Method of Use · US
2036-08-19 — Camptosar · 11344552 · Method of Use · US
2036-10-15 — Camptosar · 10456360 · US
2036-10-15 — Camptosar · 10993914 · US
2036-10-15 — Camptosar · 12059497 · Formulation · US
2036-10-15 — Camptosar · 10456360 · Formulation · US
2036-10-15 — Camptosar · 10993914 · Formulation · US

Sponsor landscape (Acetylcholinesterase reactivator (oxime) class)

Chengdu University of Traditional Chinese Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Caroxime sodium sulfonate — Competitive Intelligence Brief. https://druglandscape.com/ci/caroxime-sodium-sulfonate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab